California Public Employees Retirement System Sells 4,238 Shares of Repligen Co. (NASDAQ:RGEN)

California Public Employees Retirement System decreased its position in Repligen Co. (NASDAQ:RGENGet Rating) by 4.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,767 shares of the biotechnology company’s stock after selling 4,238 shares during the quarter. California Public Employees Retirement System owned approximately 0.18% of Repligen worth $15,877,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Harding Loevner LP grew its position in Repligen by 121.3% during the first quarter. Harding Loevner LP now owns 177 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 97 shares during the period. Cambridge Trust Co. purchased a new position in Repligen in the first quarter valued at about $38,000. Meeder Asset Management Inc. bought a new position in shares of Repligen during the 1st quarter valued at approximately $54,000. Archer Investment Corp purchased a new stake in shares of Repligen during the 1st quarter worth approximately $69,000. Finally, Signaturefd LLC raised its holdings in shares of Repligen by 37.7% in the 1st quarter. Signaturefd LLC now owns 402 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 110 shares during the period. Institutional investors own 90.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on RGEN. William Blair reissued an “outperform” rating on shares of Repligen in a report on Wednesday, November 2nd. KeyCorp boosted their price objective on Repligen from $245.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, August 3rd. StockNews.com initiated coverage on shares of Repligen in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Stephens boosted their price target on shares of Repligen from $220.00 to $275.00 and gave the company an “overweight” rating in a research report on Wednesday, August 3rd. Finally, SVB Leerink raised their price objective on shares of Repligen from $220.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $249.80.

Repligen Trading Up 0.7 %

Shares of Repligen stock opened at $175.93 on Friday. The company’s 50-day moving average price is $194.18 and its 200-day moving average price is $189.19. Repligen Co. has a 12-month low of $137.21 and a 12-month high of $300.23. The company has a market cap of $9.77 billion, a price-to-earnings ratio of 60.67, a PEG ratio of 7.92 and a beta of 1.06.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 25,000 shares of the business’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $200.00, for a total transaction of $5,000,000.00. Following the completion of the transaction, the chief executive officer now directly owns 178,265 shares in the company, valued at approximately $35,653,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Repligen news, Director Karen A. Dawes sold 775 shares of the firm’s stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $227.17, for a total value of $176,056.75. Following the sale, the director now owns 76,401 shares of the company’s stock, valued at approximately $17,356,015.17. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 25,000 shares of the firm’s stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $200.00, for a total value of $5,000,000.00. Following the completion of the sale, the chief executive officer now directly owns 178,265 shares in the company, valued at approximately $35,653,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,177 shares of company stock valued at $11,109,378. Company insiders own 1.10% of the company’s stock.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENGet Rating).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.